Nonsmall cell lung cancer (NSCLC) patients carrying an ALK mutation are treated with the drug Xalkori, which is specific for this type of mutation, whereas NSCLC patients having an EGFR mutation would receive alternative customized treatments. The gene discussed is ALK; the disease is non-small cell lung carcinoma.